NCT06551545

Brief Summary

Tryptophan is an essential amino acid needed for growth and bodily functions. It is used to make serotonin which is needed for the brain to develop and function properly. However, when the body is stressed, tryptophan is broken down into compounds that can cause harm to the brain. Premature babies who get nutrition through their vein \[i.e. total parenteral nutrition (TPN)\] can experience this type of stress. The amount of tryptophan in TPN solutions is much higher than what premature babies need and can produce too much harmful compounds. So, it is important to study the amount of these compounds made from tryptophan. But there are no methods available to study this. Therefore, the goal of this study is to develop a method to measure the compounds made from tryptophan breakdown in adults so that it can be used for preterm babies on TPN later.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for not_applicable healthy

Timeline
Completed

Started Jan 2025

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 8, 2024

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 13, 2024

Completed
5 months until next milestone

Study Start

First participant enrolled

January 1, 2025

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2025

Completed
Last Updated

March 30, 2026

Status Verified

May 1, 2025

Enrollment Period

7 months

First QC Date

August 8, 2024

Last Update Submit

March 25, 2026

Conditions

Keywords

adultshealthytryptophantryptophan breakdownindicator amino acid oxidationstable isotope

Outcome Measures

Primary Outcomes (2)

  • Fractional Synthesis Rate (FSR) of tryptophan metabolites

    Enrichment of L-\[15N2\]tryptophan and its metabolites (15N2-L-kynurenine, 15N-kynurenic acid, 15N-quinolinic acid, 15N2-serotonin and 15N-5-hydroxyindole acetic acid) in plasma and urine following orally administered tracer, L-\[15N2\]tryptophan.

    10 hours

  • Steady state

    Time at which plasma and urine enrichment of L-\[15N2\]tryptophan reaches steady-state.

    10 hours

Secondary Outcomes (2)

  • Partitioning of tryptophan metabolism

    10 hours

  • Fractional synthesis rate (FSR)

    10 hours

Study Arms (1)

Experimental: Tryptophan in healthy young adults (18-45 years)

EXPERIMENTAL

Tryptophan intake levels, up to 5 levels, will be tested in a random order in all subjects

Dietary Supplement: Tryptophan intake

Interventions

Tryptophan intakeDIETARY_SUPPLEMENT

There are 5 different tryptophan test intake levels ranging from 2, 3, 4.5, 6, 8 mg.kg-1.day.1

Experimental: Tryptophan in healthy young adults (18-45 years)

Eligibility Criteria

Age18 Years - 45 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Consent provided
  • Aged 18 to 45 years old (inclusive)
  • In good general health as evidenced by medical history, physical health and biochemistry
  • Fasting blood glucose, hemoglobin A1c (HbA1c), urea, creatinine and CRP levels within normal ranges for age.

You may not qualify if:

  • Presence of chronic disease and/or acute illness known to affect protein/amino acid metabolism (e.g. HIV, diabetes, cancer, liver or kidney disease, neurological conditions including depression and anxiety, hypo- / hyperthyroidism, inflammatory conditions,, anemia, acute cold or flu)
  • Taking medications known to affect protein/AA metabolism (e.g. steroids, anti-inflammatory medications, acetaminophen, selective serotonin reuptake inhibitors (SSRI))
  • Inability to tolerate the diet (i.e. allergy)
  • Significant weight loss during the past month or consumption of weight reducing diets.
  • Significant caffeine consumption (\>2 cups per day)
  • Significant consumption of alcohol (\>1 drink per day i.e. 1 beer or ½ glass of wine).
  • Unwilling to have blood drawn from a venous access or using a ventilated hood indirect calorimeter for the purposes of the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Hospital for Sick Children

Toronto, Ontario, M5G 1E8, Canada

Location

Study Officials

  • Glenda Courtney-Martin, PhD, RD

    The Hospital for Sick Children

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

August 8, 2024

First Posted

August 13, 2024

Study Start

January 1, 2025

Primary Completion

July 31, 2025

Study Completion

July 31, 2025

Last Updated

March 30, 2026

Record last verified: 2025-05

Locations